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Liquid Biopsy: A New Diagnostic 




Targeted molecular therapies have significantly improved the therapeutic 
management of advanced lung cancer. The possibility of detecting lung cancer at 
an early stage is surely an important event in order to improve patient survival. 
Liquid biopsy has recently demonstrated its clinical utility in advanced non-small 
cell lung cancer (NSCLC) as a possible alternative to tissue biopsy for non-invasive 
evaluation of specific genomic alterations, thus providing prognostic and predic-
tive information when the tissue is difficult to find or the material is not sufficient 
for the numerous investigations to be carried out. Several biosources from liquid 
biopsy, including free circulating tumor DNA (ctDNA) and RNA (ctRNA), circulat-
ing tumor cells (CTCs), exosomes and tumor-educated platelets (TEPs), have been 
extensively studied for their potential role in the diagnosis of lung cancer. This 
chapter proposes an overview of the circulating biomarkers assessed for the deten-
tion and monitoring of disease evolution with a particular focus on cell-free DNA, 
on the techniques developed to perform the evaluation and on the results of the 
most recent studies. The text will analyze in greater depth the liquid biopsy applied 
to the clinical practice of the management of NSCLC.
Keywords: liquid biopsy, NSCLC, cfDNA, ctDNA, biomarkers
1. Introduction
In the era of precision medicine, the management of cancer patients has 
 dramatically changed. An increasing number of prognostic and predictive bio-
markers are being implemented in order to ensure the best treatment option for 
advanced stage cancer patients and pathologists have learned to refine their reports 
[1]. To date, the analysis epidermal growth factor receptor (EGFR) gene mutations, 
anaplastic lymphoma kinase (ALK), and ROS 1 proto-oncogene (ROS1) rear-
rangements and schedules the state of death-ligand 1 (PD-L1) is capital for clinical 
decision making [2, 3]. In addition to these biomarkers, other activating mutations 
harbored by other clinically relevant genes are under investigation in clinical trials. 
However, despite the rapid development of this field in terms of discovered predic-
tive biomarkers and platforms, tissue still remains an issue. To date, tissue samples 
represent the “gold standard” starting material to obtain nucleic acids (DNA and 
RNA) for molecular purposes and the only matherial available for morphological 
diagnosis and molecular analisys is often represented by paucicellular samples 
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(cytological speciments or small tissue histological biopsies) [4]. However, a not 
negligible percentage, about 30%, of advanced stage NSCLC patients, cannot be 
tested because tissue sample is not adequate both for anatomo pathological revi-
sion and for molecular analysis [5]. In addition, even in high expertise centers, the 
percentage of inadequate molecular results, in particular when small tissue samples 
are adopted, may be significant [6]. In this setting, and in order to avoid to leave 
patients behind, liquid biopsy represents a valid option as a rapid, noninvasive and 
accurate clinical option. Several biosources from liquid biopsy, including free circu-
lating DNA (cfDNA) and RNA (cfRNA), circulating tumor cells (CTCs), exosomes 
and tumor-educated platelets (TEPs), can be isolated. While each of these modali-
ties has the potential to provide new diagnostic information and their exploration 
is highly encouraged, ctDNA certainly represents the most mature example of the 
survey on liquid biopsy in clinical practice for lung cancer patients. Therefore, this 
chapter will mainly focus on the clinical value of the free circulating tumor DNA 
(ctDNA), a small fraction of cfDNA extracted from plasma samples and we will 
review the available data that suggest the role of liquid biopsy in the management 
of NSCLC.
To date, Food and Drug Administration (FDA) has approved the analysis of 
ctDNA in two different NSCLC patients settings: naïve advanced stage NSCLC 
(basal setting), when tissue is not available or inadequate for molecular analysis of 
the Epidermal Growth Factor Receptor (EGFR) in order to select patients for first 
or second generation EGFR tyrosine kinase inhibitor (TKI) administration; acquisi-
tion of somatic resistance mechanism after first or second EGFR TKI administra-
tion (resistance setting), in order to detect the EGFR exon 20 p.T790M resistance 
point mutation and select patients for third generation EGFR TKIs [7].
Here we will report the potential of liquid biopsy to help manage NSCLC 
throughout all stages: cancer screening, minimal residual disease detection to guide 
adjuvant treatment, early detection of relapse, systemic treatment initiation and 
monitoring of response (targeted or immune therapy), and resistance genotyping. 
Moreover, we will also carefully analyze each step of the pre-analytical management 
of liquid biopsy specimen, (sample collection, ctDNA extraction, and molecular 
analysis) and the advantages and disadvantages found in the use of liquid biopsy 
respect the adoption of gold standard tissue sample in the context of clinical 
practice.
2. Liquid biopsy: definition
The term liquid biopsy refers to the use of biological fluids as a surrogate for 
neoplastic tissue to obtain information useful for diagnostic, prognostic purposes or 
to predict the response to therapy with specific anticancer drugs. In the biological 
fluids (blood, urine, saliva, cerebrospinal fluid, pleural effusions, ascites or cytol-
ogy specimen-derived supernatant [8–10] of tumor patients are contained cell-free 
DNA (cfDNA), circulating tumor DNA (ctDNA)circulating tumor cells, circulating 
RNA, microRNAs (miRNA), platelets and exosomes, which can be a valuable source 
of information about molecular assessment of cancer. Analysis of ctDNA contained 
in the free circulating DNA (cfDNA) that can be isolated from peripheral blood, 
represents to date the main liquid biopsy approach employed in clinical practice. 
In healthy patients, cfDNA is released in low quantity from normal cells during 
cellular turnover and is represented by small DNA fragments (150–200 base pairs). 
On the otherwise cancer patients show an increased levels of cfDNA [11, 12] with 
a consistent release of ctDNA generally represented, by more small fragment, 
with sizes ranging from 90 to 150 base pairs [13]. The amount of ctDNA is variable 
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in cancer patients, ranging from less than 0.1% to more than 90% [11, 12]. The cf./
ctDNA ratio can depends on the time of sample collection and clinical condition of 
the patient and is influenced by total tumor burden, location and extent of metasta-
ses, proliferation rate, apoptotic potential and genome instability [14]. ctDNA can 
enter the bloodstream through two different mechanisms: by a passive mechanism 
derived from apoptosis and necrosis or by an active mechanism derived from a 
spontaneous release of DNA fragment from primary tumor tissues or from circulat-
ing tumor cells or tumor-associated macrophages [15, 16].
2.1 Liquid biopsy versus traditional biopsy
The new College of American Pathologists (CAP), International Association for 
the Study of Lung Cancer (IASLC)/Association for Molecular Pathology (AMP) 
guideline for molecular testing of patients with NSCLC, although did not recom-
mend the performance of molecular analysis when tissue is available, they strongly 
suggest liquid biopsy in those cases where tissue sample is not adequate to perform 
molecular analysis [17] In fact, a significant subgroup of patients cannot undergo 
a biopsy or rebiopsy for several reasons such as unsuitable clinical conditions or an 
unfavorable tumor site such as bone or central nervous system or multiple small 
pulmonary nodules that are not safely amenable to biopsy [18].
Let us see what are the advantages and disadvantages of using liquid biopsy.
Liquid biopsy shows several advantages over that traditional biopsy:
• the procedure is not invasive, as it is a simple blood sampling and than may spare 
the patient an invasive procedure with the incumbent risks of major complica-
tions. Often occurs that patient need a rebiopsy due to the scant tumor tissue to 
obtain new tissue for further tests and to performing all the required analyses;
• the ability to represent more comprehensively than tissue biopsy the molecu-
lar heterogeneity of the disease. Several studies have compared mutational 
profiles of different sites of metastatic disease from the same patient and have 
established the intratumoral heterogeneity and spatial and temporal tumor 
heterogeneity of solid tumors [19, 20]. While tissue only offers a snapshot of 
the tumor at a given time and location, may not represent the complex genetic 
profile of a patient’s tumor and can introduce the hypothesis of false-negative 
results, ctDNA that is shed into the periphery from multiple sites of disease 
has the potential to overcome both spatial and temporal tumor heterogeneity. 
Circulating markers are more effective in depicting the emergent biology in 
actively growing metastatic lesions which may be missed [21, 22].
• can follow subclonal evolution through iterative noninvasively blood draws 
taking into account different clones present within all metastatic sites as a sur-
rogate for more invasive tissue biopsies. It can be usefull to monitor molecular 
evolution of the disease, although there is no evidence to date that addresses a 
modify the therapeutic choice, in the absence of clinical progression of disease;
• as a cost-effective alternative for patients considering that performing a tissue 
biopsy is considerably more expensive than a blood draw;
• turnaround time may be shorter considering the scheduling time involved [23].
• However, ctDNA suffers of several limitations that may impact on the adoption 
in routine predictive laboratory practice:
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• the amount of ctDNA in the context of cfDNA is often extremely limited, 
(<0.5% of the total circulating cell free DNA) [24] depending on both the 
volume and the localization of the disease and this can lead to misinterpret 
molecular results (false negatives);
• ctDNA has a very low half-life (about 15 minutes) and this is a crucial limita-
tion [24]. This aspect lead to reduce of 50% cfDNA molecules each 15 minutes 
from the withdrawn.
The International Association for the Study of Lung Cancer (IASLC) established 
in a statement paper the guideline when considering to adopt liquid biopsy samples 
for molecular analysis [7].
3.  What are the methods for ctDNA analysis? Pre-analytical 
consideration: from blood collection to ctDNA
CtDNA can be extracted from various biological fluids. However, the procedures 
more standardized in clinical practice concern isolation of ctDNA from peripheral 
blood. ctDNA can be isolated from serum or plasma. Several studies compare 
cfDNA levels in plasma and serum samples and have shown significantly higher 
cfDNA concentrations in serum [25, 26] but shown that the use of plasma is prefer-
able to serum. In the latter, in fact, the coagulation process causes the release of 
genomic DNA deriving from leukocytes and leads to a contamination of germline 
DNA that causes a ctDNA dilution.
Isolation and enrichment of ctDNA is a great challenge given the high degree of 
cfDNA fragmentation and its low concentration in the bloodstream to the extent of 
a few ng/ml, of which the ctDNA is alone a fraction [15]. Several factors affect the 
quality and quantity of ctDNA including: the burden of disease, the rate of release 
of the ctDNA in the bloodstream and the levels of DNA released by non- trans-
formed cells. Therefore, for these reasons the pre-analytical phase must be carefully 
checked. to achieve superior quality results.
3.1 Sample collection
A first problem that can affect the quality of the sample is constituted from 
hemolysis that can occur during phlebotomy. It is necessary, therefore, that blood 
sampling is carried out by highly qualified personnel.
The sample can be collected in standard EDTA tubes or using tubes containing 
special fixatives, capable of stabilizing the blood and the cfDNA for several days. If 
the sampling is carried out using standard tubes, one important factor must be taken 
into account. cfDNA has a short half-life, estimated at around 2.5 hours therefore 
tubes can be stored before plasma isolation for a maximum of 3 hours at room tem-
perature (Figure 1). Several studies have shown that after three hours of sampling, 
the wild-type cfDNA concentration could increase due to lysis of hematological cells 
thus reduce the relative percentage of tumor-specific ctDNA [27]. The storage of 
blood at a temperature of 4°C it does not prevent leukocyte lysis. Operators dealing 
with blood collection, handling, and eventual shipping should be cognizant of these 
time constraints. Blood should never be frozen before plasma extraction.
3.2 Extraction, quantification and storage of cfDNA
There are many methods for extracting cfDNA, which include both the use of 
commercial kits and protocols developed by laboratories.
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The extraction method must be very reliable and must generate as much  possible 
DNA of the sample under examination. For the extraction and purification of 
cfDNA from plasma they are now available various commercial kits dedicated to 
this specific use. These kits are generally based on the use of columns equipped with 
silica membranes in association with a vacuum pump, or on the use of magnetic 
balls for the capture of nucleic acids.
Once extracted, the cfDNA must undergo quantification in order to optimize 
the amplification process and to know if the subsequent molecular analyzes may be 
possible starting from the cfDNA extract [28].
Optimal storage of cfDNA is very important as it allows its use also a time to 
carry out further molecular investigations, The process takes adequate equipment, 
including −20° C/ -80° C freezers, devices graphic temperature control, acoustic 
alarm systems, quality controls of the biological material stored [28].
4. Analytical methods for detecting ctDNA
Until recently, the available technology was not sensitive enough to detect 
ctDNA and use it in a meaningful way but in recent years highly sensitive blood-
based assays have been developed to test cfDNA at very low concentrations for most 
genomic abnormalities and advances in pre-analytical processes and purification 
methods have enabled the capture, amplification and sequencing of ctDNA to be 
successful. A good molecular ctDNA test should retain an acceptable concordance 
to molecular testing in the tumor tissue. However, even with the increased sensitiv-
ity, a negative result from ctDNA analisys is not sufficient to exclude the potential 
existence of a driver alteration; therefore, in these circumstances tissue analysis 
should be performed.
The methods currently used to detect or measure ctDNA are numerous and can 
be divided into two categories: polymerase chain reaction (PCR)-based techniques 
and next-generation sequencing (NGS) technologies.
4.1 Polymerase chain reaction (PCR)-based techniques
Within the PCR-based techniques are included real time PCR, digital PCR 
(dPCR), droplet digital PCR (ddPCR), peptide nucleid acid (PNA) clamp-based 
PCR assay (Taqman assay), beads, emulsions, amplification and magnetics 
Figure 1. 
Incidence of time withdrawn in the managment of liquid biopsy specimen. The figure shows the comparison 
between electhropherograms performed by nanofluidic platform Tapestation 4200, (Agilent, Santa Clara, 
California, USA) on a sample immediately and after 1 h processed to isolate cfDNA respect time of withdrawn. 
In the left profile, ctDNA peak of 180–200 bp is inspected; on the right profile the peak is not detected.
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(BEAMing). PCR-based approaches, can detect mutations in cfDNA at allele 
frequencies of 0.01% or lower. Although there are numerous platforms currently 
for ctDNA evaluation, the gold standards in pcr-based technologies are basically 
quantitative PCR (qPCR) and digital PCR.
4.1.1 PCR real time
PCR-based tests generally have faster response times and are less expensive, but 
can typically evaluate only one or a few specific mutations at a time. The analysis of 
point mutations or small insertions/deletions on ctDNA it can be often conducted 
through the use of Real Time technologies PCR, often modified to increase the 
sensitivity of the test. There are commercially available ctDNA kits based on differ-
ent amplification technology (e.g. Refractory Mutation System ARMS/SCORPION) 
which detect mutations against EGFR exons 19, 20 and 21. These kits allow the 
co-amplification of one or more mutated alleles and of an endogenous control gene. 
The analysis with these kits allows to detect low percentages of mutated allele in 
the presence of high amounts of wild-type genomic DNA and can reach an even 
lower limit of detection (LOD) 0.5%. The main limitation related to the adoption 
of this approach is related to the annealing step where probes may not able to target 
corresponding genomic region (Figure 2).
4.1.2 Digital PCR (dPCR)
Digital PCR (dPCR) is a next-generation evolution of PCR of which there are 
two technological platforms: “digital droplet PCR - ddPCR” and “BEAMing dPCR” 
(Beam, Emulsion, Amplification, Magnetics).
Both methods, utilize emulsion technology to quantify the amount of mutant 
cfDNA in patient plasma and are based on the limiting dilution of DNA with a 
distribution of the sample in thousands of homogeneous “droplets” in an oil–water 
Figure 2. 
Visual inspection of p.T790M EGFR acquired resistance mutations by using NGS system. The figure shows the 
manual count of aligned reads generated by Golden helix genome browse 1.1.2 (Golden helix genome browse 
Inc). In the red box is reported a polymorphism in the genomic region near p.T790M base change (blue box). 
Although the presence of this polymorphic alteration, NGS platform is able to p.T790M resistance mutation 
while RT-qPCR based approaches report a false negative result.
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emulsion. These characteristics are of great importance in the context of the 
analysis of ctDNA, where it is necessary to search for and amplify rare molecules of 
tumor DNA in the presence of a large excess of wildtype germline DNA.
In fact, the breakdown of the sample into droplets has the function of reduce 
competition between mutated tumor DNA and wild-type DNA increasing the 
specificity and sensitivity of the analysis.
Both of these experimental approach is very useful for the identification of rare 
variants since only a small concentration of template is required for the analysis.
The sensibility and the specificity of the tests with ddPCR and BEAMing dPCR 
are, respectively 0.1% and 0.01%.
Several studies have compared multiple platforms for detecting EGFR mutations 
in plasma ctDNA. In one study, two non-digital platforms (cobas®EGFR mutation 
test and therascreen EGFR amplification refractory mutation system test) and two 
digital platforms (Droplet Digital PCR and BEAMing digital PCR) were compared 
in their ability to identify sensitizing mutations and the results support the poten-
tial use of both platforms in a clinical development program [29].
The limit of these technologies is that of their limited ability to detect complex 
genomic alterations and perform multiplex testing.
4.2 NGS in liquid biopsy
In contrast to PCR-based methods, NGS is a fascinating technology able to 
analyze different biomarkers for different patients, simultaneously [30] and detect 
rare and previously uncharacterized alterations. NGS are capable of detection of 
mutations, indels, copy number variations and genomic rearrangements such as 
oncogenic fusions. Another advantage of an NGS approach is the possibility to 
quantify the amount of DNA that brings a particular alteration.
This technology, based on massive and parallel sequencing, ensures a high 
sequencing throughput, by generating from hundreds of thousands to millions of 
sequences (reads) [30]. To overcome the limitations of ctDNA, next generation 
sequencing (NGS) may be a viable option. The use of NGS for liquid biopsy requires 
changes to the protocols normally used for blood and tissue analysis. Operational 
protocols dedicated to liquid biopsy.
Different NGS platforms are commercially available and validated on liquid 
biopsy samples [31]. Among these, Illumina (San Diego, California) platform 
adopts a sequencing-by-synthesis chemistry able to identify DNA bases, while 
introducing them into a nucleic acid strand, by adopting a system of fluores-
cently labeled nucleotides; Ion Torrent (ThermoFisher Scientifics, Waltham, 
Massachusetts) platform adopts a sequencing-by-synthesis chemistry able to 
identify DNA bases, while introducing them into a nucleic acid strand, by adopt-
ing a semiconductor system useful to measure a change in pH due to the release of 
an H+ ion [32]. Important differences exist between these various platforms with 
respect to the number of genomic alterations included in a single panel, the ability 
to multiplex these assays, the turnaround time of the test, and its ability to detect 
complex genomic alterations.
Different NGS gene panels have been adopted for ctDNA analysis and numerous 
studies have been carried out in recent years to validate concordance to molecular 
testing in the tumor tissue. A higher sensitivity and specificity was obtained by 
Reckampet al by using a short footprint mutation enrichment NGS assay to analyze 
ctDNA samples extracted from plasma of NSCLC patients [8]. On the overall, 
taking into account the results obtained on matched tissue samples, a sensitivity of 
93, 100, and 87% for EGFR exon 20 p.T790M, EGFR exon 21 p.L858R, and EGFR 
exon 19 deletions, was reached. The specificity, for the same mutations was 94, 100, 
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and 96% [8]. In the experience of Paweletz et al. a high sensitivity (86% and 79%) 
and specificity (100% and 100%) was obtained by using a targeted NGS approach 
on NSCLC patients for EGFR and KRAS mutations [33]. Another valid approach is 
represented by the use of narrow gene panels. In the experience of the Predictive 
Molecular Pathology Laboratory at the University of Naples Federico II a custom, 
narrow NGS gene panel (named SiRe®), that cover 568 clinical relevant muta-
tions in six genes (EGFR, KRAS, BRAF, NRAS, KIT and PDGFRA), was routinely 
employed for both tissue and liquid biopsy testing [34, 35]. In the validation 
study on different tumor types, a sensitivity of 90.5% and a specificity of 100% 
was reached by comparing results obtained on ctDNA extracted from serum and 
plasma with those obtained on matched tissue samples. In addition, this panel may 
be useful to detect EGFR and KRAS actionable mutations in basal setting NSCLC 
patients [35].
Ultra-sensitive NGS techniques dedicated to analysis have been developed of the 
ctDNA. The characterizing element of Cancer custom profiling deep sequencing 
(Capp-Seq), its is a selector that identifies different classes of somatic mutations 
with sensitivity and specificity greater than 90%. Similar results in terms of sensi-
tivity and specificity were achieved with Tagged-amplicon deep sequencing (Tam-
Seq) and Safe-Sequencing techniques System (Safe-SeqS).
What was once a limitation of ngs technology, the turnaround time is now 
acceptable for clinical management — approximately 13 days — and costs have been 
significantly reduced [36]. Also the difficulty of analyzing the numerous informa-
tion deriving from the multigene panels has also been overcome since a variety of 
publically available and proprietary bioinformatics tools have been developed to 
assist in these calculations.
4.3 New emerging technologies to the study of liquid biopsy
Several studies today aim to overcome the current limits of sensitivity for liquid 
biopsy, to support extensive research and clinics applications. Although for the 
evaluation of the ctDNA the gold standards are basically quantitative PCR (qPCR), 
digital PCR and NGS to these have been added many technologies such as whole 
genome sequencing (WGS) [37], Rare Ep iAlleles by Melt qPCR (DREAMing) [38] 
and bidirectional pyrophosphorolysis activated polymerization (bi-PAP).
Moreover, of great interest in biomedicine applied to the study of liquid biopsy 
are the PCR-free methods [39]. Several articles have been published dealing with 
PCR-free methods for the detection of point mutations [40]. These methods 
applied alternative isothermal-amplification methods whitch do not require 
thermal cycling to avoid heating and cooling steps. About the smetods include those 
based on nucleic acid sequences polymerization (NASBA), loop-mediated amplifi-
cation (LAMP, helicase-dependent amplification (HAD), rolling - circle amplifica-
tion (RCA), recombinase-polymerase amplification (RPA) and multi-displacement 
amplification (MDA), isothermal displacement of the circular filament polymeriza-
tion (ICSPD).
Among these methods of sure interest is surface plasmon resonance imaging 
(SPR-I). This tecnology are able to detected Attomolar concentrations of target 
genomic DNA, demonstrating the ultra-sensitivity of the new method [39].
Thanks to these new ultra-sensitive technologies, several authors are pushing 
towards new horizons. In some studies differences in fragment lengths of circulat-
ing DNA could be exploited to enhance sensitivity for detecting the presence of 
ctDNA and for noninvasive genomic analysis of cancer. Mouliere et al. [13] argue 
that cfDNA fragment size analysis improved the discrimination between samples 
from patients with cancer and those from healthy individuals.
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All these technologies are now supported by different platforms and have 
already been approved for clinical use [41]. However, the lack of standardization 
limit the clinical implementation for most of these methodologies.
5. Liquid biopsy in clinical practice
There are two main scenarios in which the liquid biopsy might confer an 
advantage to NSCLC advanced patients:at initial molecular profiling and at progres-
sion during targeted therapy. To date, Food and Drug Administration (FDA) has 
approved the analysis of ctDNA extracted from plasma samples in two different 
patient settings: in treatment naïve advanced stage NSCLC (basal setting), when 
tissue is not available or inadequate for molecular purposes, for the Epidermal 
Growth Factor Receptor (EGFR) gene assessment in order to select patients for 
first or second generation EGFR tyrosine kinase inhibitor (TKI) treatments and in 
advanced stage NSCLC resistant to a first or second EGFR TKI (resistance setting), 
in order to detect the EGFR exon 20 p.T790M resistance point mutation and select 
patients for third generation EGFR TKIs [7].
5.1 Tumor molecular profiling of naïve patients (basal setting)
Liquid biopsy should be taken into consideration at the time of initial diagnosis 
in all patients who need tumor molecular profiling, but:
• tumor tissue is insufficient or unavailable;
• in patients for whom invasive procedures may be risky or contraindicated;
• in those cases where the biopsy scheduling time exceeds two weeks causing a 
serious delay in diagnosis;
• in the case of bone biopsies where the decalcification processes of the sample 
irreversibly damage the nucleic acids and therefore invalidate any molecular 
investigation;
• moreover, indications for choosing treatment-naive patients for ctDNA molec-
ular testing are all patients with advanced/metastatic nonsquamous NSCLC 
and patients with squamous NSCLC if never smoker and/or younger age.
In clinical practice, liquid biopsy is currently mainly used for analysis of 
mutational status of the epidermal growth factor receptor (EGFR) in advanced 
NSCLC patients. Several studies and meta-analyzes [42, 43] have evaluated the 
diagnostic accuracy of ctDNA analysis for the identification of the most frequent 
activating mutations of the EGFR gene (deletions of exon 19, L858R of exon 21) 
in patients naïve with advanced NSCLC proving a good specificity greater than 
90%. Sensitivity results instead be lower, with fluctuations between 50% and 80% 
depending on the technology used. On the basis of these evidences the evaluation of 
the mutational status of the EGFR gene on liquid biopsy is currently recommended 
as a possible alternative to analysis on tumor tissue.
A positive finding of an actionable mutation in ctDNA, if using a validated 
assay, is sufficient to initiate targeted treatment. However, a negative result it can-
not be trusted and it should be followed up with a secondary test or conventional 
tumor testing. A negative result can be negative for several factors. The amounts 
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of DNA into peripheral circulation of patients with indolent slow-growing tumors 
is often insufficient for detection and these patient may be at more risk of a false 
negative compared to patients with a more disseminated cancer. Therefore, it is 
imperative that operators are aware of the possibility of a false negative result from 
the liquid biopsy.
For this reason the liquid biopsy at diagnosis is far from being able to replace 
the traditional analysis of the tissue which therefore remains the standard goal in 
patient’s diagnosis.
5.1.1  Other oncogenic drivers in NSCLC have been detected in ctDNA isolated 
from plasma
In addition to EGFR mutations a wide range of potentially actionable altera-
tions are of particular interest clinically and are detectable in patients with NSCLC, 
including ROS1, fibroblast growth factor receptor 3 (FGFR3), and neurotrophic 
receptor tyrosine kinase (NTRK) rearrangements and ALK, MEK, AKT, BRAF, 
HER2, MEK1/2, NRAS, KRAS mutations and MET receptor tyrosine kinase muta-
tions and amplification. All of these abnormalities have been detected in ctDNA 
isolated from plasma and could therefore be used for screening naive patients.
As regards the study of rearrangements, which is carried out at the ctRNA 
level, some technical difficulties may arise due to the low stability of the circulat-
ing plasma RNA which easily undergoes degradation. The most commonly used 
techniques to identified ALK at the time of diagnosis, are qPCR and digital PCR or 
next-generation sequencing (NGS) approaches [44, 45].
The sensitivity of the techniques for studying this alteration is less high than 
those that can normally be used on the tissue (e.g., immunohistochemistry or 
Fluorescent in situ Hybridization (FISH).
5.1.2 The liquid biopsy in other fluids
Although plasma is the most widely used fluid sample for liquid biopsy, other 
samples are available such as urine, sputum, cerebrospinal fluid or pleural effusion 
as a source of ctDNA.
Sputum is an important source of nucleic acids and different studies investi-
gated EGFR status in NSCLC patients. Wu et al. [46] identified a high concordance 
between sputum and tissue samples (74%). In a recent study it has been identified 
the potential role as a diagnostic biomarker for NSCLC of P16INK4 gene promoter 
methylation in both bronchoalveolar lavage (BAL) and sputum [47]. A recent study 
showed that sensitivity of EGFR mutation detection in the urine is comparable to 
that found in the plasma of the same patient [48] and concordance of mutations 
in the driver gene may increase when compared to plasma alone to combination of 
plasma, urine and sputum [49].
The ability to use ctDNA obtained from cerebrospinal fluid (CSF) to study 
genetic alterations and monitor response to treatment is very important as brain 
metastases are difficult to reach.
5.2 Monitoring therapeutic resistance
Resistance inevitably arises in almost all patients undergoing treatment for 
metastatic disease [50]. The ability to detect the presence of multiple resistance 
mechanisms is critical. Acquired resistance to therapy is often driven by presence 
of one or more tumor subclones that harbor resistance alterations [51]. These 
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subclones drive disease progression and may reside in the same tumor lesion or in 
different metastatic lesions [52]. Therefore, a standard tumor biopsy of a single 
lesion at the time of disease progression may fail to capture resistance mechanisms 
present in tumor cells outside of the biopsied region [53]. This is where the liquid 
biopsy comes into play overcomes the limit of tumor heterogeneity.
p.T790M gatekeeper resistance identification in liquid biopsy is currently 
employed as a first diagnostic approach in all patients with EGFR-positive advanced 
NSCLC in progression after EGFR-TKI treatment. However, due to the risk of 
“false negatives” associated with such method, all patients in whom the mutational 
analysis on ctDNA results “negative” and even the initial sensitizing mutation is 
not detected must be subjected to test tumor tissue taken by re-biopsy, in order 
to define the best therapeutic strategy. However before proceeding with the tis-
sue biopsy, it would be advisable to repeat liquid biopsy. In the absence of such a 
mutation, the test should be considered non-informative as the sample contains no 
sufficient ctDNA. In this regard, multiple studies, and a recent meta-analysis, have 
clearly highlighted as the site of metastases cancer significantly affects the diagnos-
tic accuracy of the mutation analysis of the EGFR gene performed on ctDNA. The 
sensitivity of that method in determining both activating and p.T790M mutation 
can in fact vary from 80% in presence of extra-thoracic metastases at 50% in the 
presence of exclusively intra-thoracic localizations [28]. In order to increase the 
chances of success of the liquid biopsy, the test should be performed at the time 
of obvious progression of disease, when the probability that the tumor DNA is 
released into the circulation is higher.
Liquid biopsy is also utilized to detected additional coexisting resistance altera-
tions, such as MET amplification that predicts decreased benefit from subsequent 
therapy with third-generation EGFR inhibitors and EGFR p.C797S mutation follow-
ing therapy with the third-generation EGFR inhibitor osimertinib [52].
6. How should the results of liquid biopsy be reported? The reporting
European Society of Pathology Task Force on Quality Assurance in Molecular 
Pathology and the Royal College of Pathologists published standards of molecular 
diagnostics reporting [54].
Reporting is an integral part of the diagnostic procedure and should contain the 
following information: patient identifiers, specimen type, assay methodology and 
the platform used including sensitivity and limit of detection, date of collection of 
the material used for the analysis and date of arrival of the sample in the laboratory 
that performs the analysis, methods of conservation of the sample investigated 
mutations, results of the test, data interpretation and an overall evaluation of the 
analysis specifying whether a detected alteration is clinically relevant.
The report must be completed on a predetermined form, dated and signed by 
the service manager.
7. Emerging application and future direction of liquid biopsy
Liquid biopsy is a rapidly growing field in oncology and ctDNA analysis is con-
sidered to be very promising as a biomarker for early stage detection, identification 
and monitoring of minimal residual disease (MRD), immuno-oncology, assessment 
of treatment response, and monitoring tumor evolution. Currently, several trials 
are ongoing in this field.
Pathology - From Classics to Innovations
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7.1 Potential applications in early stage NSCLC: screening
Detection of lung cancer at an earlier stage of disease, potentially susceptible of 
curative resection, can be critical to improve patients survival. Current screening and 
diagnostic tests, such as computed tomography (CT) scans and cytological/histologi-
cal analyzes could be supplemented by the specificity of cfDNA [55]. The evaluation 
of genomic anomalies, including specific mutations, in cfDNA could offer a promis-
ing, non-invasive approach for the early diagnosis of lung cancer, considering the 
high specificity of these related tumors alterations. A limitation is due to the low 
frequency of some mutations and the fact that the mutant cfDNA can be obscured by 
an excess of background wild-type DNA. However, highly sensitive approaches have 
been developed to analyze low-level mutants cfDNA, including NGS-based options.
Many studies have focused on assessing the quantities of cfDNA. In a study 
carried out on smoking patients it was shown that the concentration in cfDNA, of 
the human telomerase reverse transcription (hTERT) gene was eight times higher in 
lung cancer patients than in controls and correlate with a strong risk factor for the 
development of lung cancer [56]. In other studies it has been shown that a greater 
amount of cfDNA during surgery correlates with a worse prognosis at 5 years 
survival, selecting a more aggressive disease [57]. Using a very sensitive quantita-
tive test [57] it was demonstrated the possibility of discriminate between healthy 
subjects and NSCLC patients by measuring the quantities of cfDNA [58, 59]. cfDNA 
were significantly higher in NSCLC patients compared to healthy controls.
Methylation is an early and frequent epigenetic alteration that can be detected 
in cfDNA, including in plasma [60, 61]. Epigenetic modifications, regulate the 
expression of a large number of genes involved in malignant transformation and 
carcinogenesis. DNA alterations in methylation occur early in carcinogenesis and 
are remarkably more stable than other potentials diagnostic biomarkers.
Several studies have evaluated the methylation levels of single or panels of tumor 
suppressor genes in plasma or serum from lung cancer patients. Several genes have 
been found to be differentially methylated in cfDNA between patients with lung 
cancer and controls including MGMT, p16, RASSF1A, DAPK, RAR-β, DCLK1, 
SHOX2 and septin9 [62, 63]. In a recent study, a methylation panel of six genes 
showed a sensitivity of 72% for the detection of stage Ia NSCLC [64].
However though, methylation changes can also occur in the DNA of peritumor 
normal tissue which can therefore interfere with the analysis of tumor DNA gener-
ating a false positive result [65]. Considering together the fact that ctDNA is absent 
or very low in the early stages, the possibility to detect mutations in cfDNA derived 
from non tumor cells and the lack of standardized methods and large validation 
studies the analysis of ctDNA has not been introduced in the clinic screening yet.
7.2 Identification and monitoring residual disease
Measurement of residual disease after primary tumor treatment is an area of 
active investigation.
Efficient methods of identifying MRD in patients treated with surgery or adju-
vant chemotherapy are currently lacking. Mutation monitoring can be a significant 
predictor of early relapses and MRD. Several studies have focused on detecting 
these mutations in ctDNA as an early indicator of relapse and a potential marker of 
residual disease.
Monitoring of ctDNA for residual disease has been used in several studies in 
lung cancer. Presence of ctDNA after local treatment was highly predictive of 
disease recurrence in a small cohort of lung cancer patients with stage I-III lung 
undergoing local treatment with radiation, surgery, or both [66].
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A prospective trial is ongoing to investigate the ability of ctDNA mutations and 
methylation monitoring to detect MRD after surgery for stage Ia–III NSCLC [67].
The limit of the use of ctDNA in detect MRD in clinical practice beyond is the 
lack of circulating tumor specific alterations.
7.3 Monitoring treatment response and cancer progression
CtDNA analysis could be a way to monitor cancer status in real time. Methods 
for monitoring treatment response and changes in tumor burden with cfDNA 
involve the identification of genomic alterations specific to an individual patient’s 
tumor and the relationship between changes in ctDNA levels, that can be monitored 
in real time during therapy (Figure 3).
In one study, long-term monitoring of a patient with NSCLC for analysis of 
EGFR mutations (p.L858R and p.T790M) using ctDNA isolated from serum and 
plasma a close correlation with the onset of metastasis was identified. In another 
study carried out with NGS technology on plasma-derived ctDNA from 168 patients 
with different types of cancer, the molecular alterations identified correlated to 
which of tissue [68].
ctDNA levels drop dramatically after one to two weeks in patients responding to 
treatment [69, 70]. Some authors suggested that a rise in ctDNA levels may precede 
radiographic progression.
Data obtained by several studies, conducted on different tumor type [71] using 
very sensitive new technologies involving multiplexed mutation-specific PCR and 
NGS suggest that the additionof ctDNA monitoring into clinical care could be a 
valuable tool to more accurately predict patient response and detect progression.
7.4 Liquid biopsy and immuno-oncology
Cancer immunotherapy is certainly the most profound innovation recorded in 
recent years in the fight against cancer. The recent use of anti-programmed death 
Figure 3. 
Molecular follow up of a NSCLC patient. The figure shows the behavior of inspected molecular alterations 
[exon 19 deletion (blue line) and p.T790M point mutation (red line)] analyzed by serial liquid biopsy 
specimens in relation to the clinical outcome of a NSCLC patient.
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receptor-1 (PD-1) /PD-1 ligand 1 immune checkpoint inhibitors (IC) in clinical 
trials indicates their efficacy in immune therapy against cancer.
These immune checkpoint inhibitors have been shown to have an effective 
therapeutic response, particularly in tumors with high tumor mutation burden 
(TMB) [72]. If the ctDNA can be used to guide and monitor immune therapy is just 
beginning to be evaluated [73].
In several studies, tumor mutation burden (TMB) can be estimated from ctDNA 
with good concordance with tissue results [74, 75]. Moreover, the identification of 
a high TMB in the ctDNA correlates closely with the two inhibitors of programmed 
cell death (PD)1 and its ligand (PD-L1) [74].
In a recent study it was shown that ctDNA TMB it has a closer correlation with 
metastatic tissue than primary tumor. Furthermore, this concordance is greater in 
cases with high ctDNA concentrations [76].
Another possible application of ctDNA in immunotherapy is in response moni-
toring. Has been proven a good correlation between ctDNA modification and clini-
cal response. Some studies show indeed that the amount of cfDNA correlate with 
the response to immunotherapy and a decrease of cfDNA was an indicator of good 
response. Moreover, also chromosomal instability, predictive for immunotherapy 
response canbe evaluated by NGS in cf-DNA [77, 78].
A new interesting area is represented by the evaluation of tumor microenviro-
ment adopting liquid biopsy specimen in the clinical administration of lung cancer 
patients. Cai et al. compared IC positive outcome and inflammation markers (INFγ, 
lymphocites ratio CD4/CD8) in relation to the conventional target biomarkers 
(PD-L1, CTLA4) for the selection of lung cancer patients to IC administration. 
They showed that a wide range of inflammatory biomarkers may integrate clinical 
outcome in NSCLC patients clinical administration [79].
Other applications of cfDNA are likely to emerge in the near future, in the field 
of immuno oncology such as the detection of minimal residual disease for adjuvant 
immunotherapy, and the identification of resistance mechanisms linked to the 
onset of new mutations such as the acquired JAK1/2 or B2M mutations [73].
However, in this context it is not yet possible to think of a complete replacement 
of the liquid tissue biopsy. The tumor biopsy will have more and more value, both in 
the evaluation of PD-L1 expression on tumor cells and in the analysis of the tumor 
microenvironment.
And while it is possible to identify resistance mechanisms as acquired mutations 
in the blood, however, acquired resistance could be linked to dynamic changes in 
the microenvironment, which cannot be detected by a simple blood draw.
7.5 Liquid biopsy in the management of other tumors
Several pre clinical studies were performed in order to evaluate the role of 
cfDNA in the management of other tumor patients.
Wang et al. [80] demonstrated that ctDNA may be considered a diagnostic bio-
marker in head and neck squamous cell carcinoma (HNSCC) patients. 93 saliva and 
matching blood specimens were collected from HNSCC patients to identify somatic 
mutations in genes (TP53, PIK3CA, CDKN2A, HRAS, NRAS) that could play a 
potential clinical role in the management of this patient cohort. Results showed that 
ctDNA was successfully isolated from 76% and 87% of saliva and plasma samples, 
respectively. The authors, highlighting a percent detection rate for hot spot muta-
tions of 100% and 76% for saliva and blood specimens respectively, defined how 
cfDNA extracted from saliva samples may be considered a reliable tool to identify 
HNSCC malignant lesions in early stage setting. Similarly, Salvi et al. [81] discussed 
how cfDNA may be adopted in early stage section for prostate cancer patients by 
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elucidating an accuracy of 80% to discriminate cancer patients from benign lesions. 
In addition, Christensen et al. [82] showed how a digital droplet PCR approach 
is suitable to identify somatic alterations in urine cell free DNA (Ucf-DNA) by 
demonstrating how a correlation between Ucf-DNA alteration and tumor stage, 
size and grade, were statistically significant. In relation to this section, stool DNA 
also represents a promising diagnostic tool to early detect colorectal carcinoma 
patients in the early stage. According to this point, Imperiale et al. [83] showed 
that the sensitivity of novel technical approach DNA-based were characterized by 
higher analytical performance in the analysis of both CRC (92.3%) and advanced 
precancerous lesions (42.4%) respect the conventional screening test commercially 
available.
8. Conclusion
Is tissue still the issue?
One of the key questions facing oncologists today is whether ctDNA can replace 
biopsy or ribiopsy in clinical practice.
Liquid biopsy resulted improvements in the management of patients with 
NSCLC, offering an alternative to standard procedures in cases where tissue biopsy 
samples are insufficient or not feasible and providing a quick and dynamic assess-
ment of emerging resistance mechanisms that can be used for guide treatment 
decisions so has been suggested to be included in clincal practice. However the 
fields of investigation using liquid biopsy are still restricted in routine practice. To 
date, FDA has approved the analysis EGFR gene assessment that is currently based 
on standardized and international practices recommendations and authorizes the 
administration of TKI. Recently, a document of the IASLC, stated that an EGFR, 
ALK, ROS1 or BRAF positive result of an NGS liquid biopsy analisys should be 
considered adequate for initiating first-line therapy in advanced NSCLC.
Although we can firmly state that liquid biopsy is a great help in NSCLC 
patient managing, however, in our opinion, for now it cannot replace tissue 
biopsy, which will remain the gold standard. Especially in the context of diagnosis 
where the definition of the tumor subtype can only be clarified through a cyto-
morphological analysis and immunohistochemical criteria. Furthermore, even 
the exact stage of cancer can only be obtained with tissue sampling. Moreover, in 
the setting of detect EGFR-sensitizing alterations in peripheral blood a negative 
plasma test it should be considered non-informative and will always need tissue 
confirmation.
Moreover, results of clinical studies have highlighted the existence of significant 
critical issues in the execution of a mutational test on liquid biopsy, either in the 
pre-analytical phase both in the analytical phase. Standardization of the various 
stages of the process is fundamental. It is certainly important that the analysis be 
performed in laboratories highly specialized, who already have experience in using 
highly sensitive molecular techniques in order to avoid false positives or false nega-
tives results.
As indicated, there are numerous methods of studying circulating nucleic acids. 
In view of the large number of actionable targets in NSCLC, guidelines support the 
position that broad-based testing by NGS. The NGS technique requires workflow 
complex and use of multigene panels also requires the use of sophisticated software 
and, sometimes, the help of bioinformatics.
So it is therefore evident that the choice between the different technologies must 
hold account of their sustainability and the clinical use required in the context in 
which you operate.
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ies and detailed functional studies.
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